Remove tag artificial-intelligence-drug-discovery
article thumbnail

AI-Powered Precision Engagement in Commercial and Medical Functions

Intouch Solutions

It has continually evolved, embracing new technologies and methodologies to improve drug discovery, development, and distribution. Pre-Clinical : Deeper comprehension of the impacts and outcomes associated with a particular drug. Clinical : Optimized efficiency, inventory management, and service quality of clinical trials.

article thumbnail

New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW

Drug Discovery World

A series of short seminars focused on automation and technology will be available to visitors at Drug Discovery 2022 which takes place at the ExCel, London 4 and 5 October. will discuss The role of AI and Automation in Personalised Medicine: How can AI Help in the Post- Drug Discovery Process. Fellowship Programme.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

article thumbnail

AI is critical to solving new complexities in drug discovery

Drug Discovery World

Andrew A Radin Chief Executive Officer of Aria Pharmaceuticals, on the critical use of artificial intelligence in solving some of drug discovery’s most new and complex challenges. It also carries a much higher price tag for failure. We have the tools at our disposal to meet this challenge.

Drugs 52
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.